Stock Price
237.00
Daily Change
-3.30 -1.37%
Monthly
-8.39%
Yearly
49.48%
Q2 Forecast
231.88

UCB reported EUR1.08B in Net Income for its fiscal semester ending in December of 2025.





Net Income Change Date
Alcon AG USD 189M 28M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
argenx SE USD 366M 166.95M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Genmab DKK 31M 370M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
GRIFOLS EUR 73M 25.25M Mar/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 319M 583M Dec/2025
Novartis USD 3.16B 747M Mar/2026
Orion EUR 90.4M 170.1M Mar/2026
Recordati EUR 117.31M 7.15M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
UCB EUR 1.08B 608M Dec/2025
Unibail Rodamco EUR 532.1M 123.6M Dec/2025